Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
30–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with diagnosis of idiopathic Parkinson's Disease (PD) that is levodopa-responsive
Participants must be judged by the investigator to be inadequately controlled by current therapy, have recognizable/identifiable "Off" and "On" states (motor fluctuations), and have a minimum of 2.5 hours of "Off" time per day
You may not be if
Participant is cognitively impaired and is not able to safely and effectively manage the drug delivery system and the diaries and is not able to adhere to the study
Participant is considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason
Clareo Health | A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
